Search Result

Results for "

Tbk/IKK_epsilon_-IN-1

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Autophagy (4) Bacterial (4) Endogenous Metabolite (4) HSV (1) IKK (20) NF-κB (1) PDK-1 (1) PIKfyve (1) PROTACs (1) Small Interfering RNA (siRNA) (3) STING (12) ULK (3)
By Research Areas:	Cancer (15) Infection (6) Inflammation/Immunology (14) Metabolic Disease (2) Neurological Disease (1)

Inhibitors & Agonists

Natural
Products

Antibodies

Targets Recommended: AIM2 NEKs

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-152237

TBK1-IN-1	IKK	Cancer
TBK1-IN-1 is a potent and selective TANK binding kinase 1 (TBK1) inhibitor with an IC₅₀ value of 22.4 nM. TBK1-IN-1 inhibits TBK1 downstream target genes cxcl10 and ifnβ expression. TBK1-IN-1 has anticancer activity ^[1].

HY-12453

TBK1/IKKε-IN-2

2 Publications Verification

IKK Inflammation/Immunology

TBK1/IKKε-IN-2 is a dual TBK1 and IKKε inhibitor.

TBK1/IKKε-IN-2 2 Publications Verification	IKK	Inflammation/Immunology
TBK1/IKKε-IN-2 is a dual *TBK1* and IKKε inhibitor.

HY-128679

TBK1/IKKε-IN-5	IKK	Cancer
TBK1/IKKε-IN-5 (compound 1) is an orally active *TBK1* and IKKε dual inhibitor, with IC₅₀ values of 1 and 5.6 nM, respectively. TBK1/IKKε-IN-5 enhances the blockade response to *PD-1* and induces immune memory in rats when combines with anti-PD-L1. TBK1/IKKε-IN-5 can be used in cancer research, especially in tumour immunity ^[1].

HY-124652

TBK1/IKKε-IN-4	IKK	Cancer
TBK1/IKKε-IN-4 is a 6-aminopyrazolopyrimidine derivative and a potent, selective *TBK1* and IKKε inhibitor with IC₅₀ values of 13 nM and 59 nM, respectively. TBK1/IKKε-IN-4 shows 100- to 1000-fold less activity against other protein kinases including PDK1, PI3K family members and mTOR ^[1].

HY-138931

TBK1/IKKε-IN-6

IKK Cancer

TBK1/IKKε-IN-6 (example 110) is a TBK1 and IKKε inhibitor, with IC₅₀ values of <100 nM for both TBK1 and IKKε ^[1].
HY-U00457

TBK1/IKKε-IN-1

IKK Cancer

TBK1/IKKε-IN-1 is a dual TBK1 and IKKε inhibitor extracted from patent US20160376283 A1, Compound 274 in Example 60, has IC₅₀s of <100 nM.

TBK1/IKKε-IN-6	IKK	Cancer
TBK1/IKKε-IN-6 (example 110) is a *TBK1* and IKKε inhibitor, with IC₅₀ values of <100 nM for both TBK1 and IKKε ^[1].

TBK1/IKKε-IN-1	IKK	Cancer
TBK1/IKKε-IN-1 is a dual *TBK1* and IKKε inhibitor extracted from patent US20160376283 A1, Compound 274 in Example 60, has IC₅₀s of <100 nM.

HY-112557

*PROTAC TBK1 degrader-2*	PROTACs IKK	Cancer
PROTAC TBK1 degrader-2 is a Ligands for Target Protein for PROTAC. PROTAC TBK1 degrader-2 is a potent degrader based on the serine/threonine kinase TANK-binding kinase 1 (TBK1) (DC₅₀=15 nM; K_d=4.6 nM) with a maximum efficiency of 96%. PROTAC TBK1 degrader-2 also targets to IkB kinase IKKε (IC₅₀=8.7 nM), with low selectivity over *TBK1* (IC₅₀=1.3 nM) ^[1].

HY-122706

TBK1/IKKε-IN-3	IKK	Metabolic Disease
TBK1/IKKε-IN-3 is a potent IP6K inhibitor with IC₅₀ values of 3, 8.65 and 3.72 μM for *IP6K1, IP6K2* and IP6K3, respectively. TBK1/IKKε-IN-3 can be used in the study of obesity diseases. ^[1].

HY-RS14257

TBK1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
TBK1 Human Pre-designed siRNA Set A contains three designed siRNAs for TBK1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

TBK1 Human Pre-designed siRNA Set A TBK1 Human Pre-designed siRNA Set A

HY-RS14258

Tbk1 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Tbk1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Tbk1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Tbk1 Mouse Pre-designed siRNA Set A Tbk1 Mouse Pre-designed siRNA Set A

HY-RS14259

Tbk1 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Tbk1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Tbk1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Tbk1 Rat Pre-designed siRNA Set A Tbk1 Rat Pre-designed siRNA Set A

HY-148206

DMX-129

IKK Cancer

DMX-129 is an ΙΚΚε and TBK-1 inhibitor with IC₅₀ values of <30 nM for both TBK1 and IKKε ^[1].

DMX-129	IKK	Cancer
DMX-129 is an ΙΚΚε and *TBK-1* inhibitor with IC₅₀ values of <30 nM for both TBK1 and IKKε ^[1].

HY-111941

GSK8612 10+ Cited Publications	IKK	Neurological Disease Inflammation/Immunology Cancer
GSK8612 is a highly selective and potent Tank-binding Kinase-1 (TBK1) inhibitor, with a pIC₅₀ of 6.8 for recombinant TBK1 ^[1].

HY-B0713

Amlexanox 15+ Cited Publications AA673; Amoxanox; CHX3673	IKK	Metabolic Disease
Amlexanox (AA673; Amoxanox; CHX3673) is a specific inhibitor of IKKε and *TBK1, and inhibits the IKKε and TBK1 activity determined by MBP phosphorylation with an IC₅₀* of approximately 1-2 μM.

HY-133117

BAY-985	IKK	Cancer
BAY-985 is a highly potent, orally active and selective ATP-competitive dual inhibitor of *TBK1* and IKKε with IC₅₀s of 2/30 and 2 nM for TBK1 (low/high ATP) and IKKε, respectively. Antitumor efficacy ^[1].

HY-13018

MRT67307 15+ Cited Publications	IKK ULK Autophagy	Inflammation/Immunology Cancer
MRT67307 is a dual inhibitor of the IKKε and *TBK-1* with IC₅₀s of 160 and 19 nM, respectively ^[1]. MRT67307 also inhibits *ULK1* and ULK2 with IC₅₀s of 45 and 38 nM, respectively. MRT67307 also blocks autophagy in cells .

HY-13018A

MRT67307 hydrochloride	IKK ULK Autophagy	Inflammation/Immunology Cancer
MRT67307 hydrochloride is a dual inhibitor of the IKKε and *TBK-1* with IC₅₀s of 160 and 19 nM, respectively ^[1]. MRT67307 hydrochloride also inhibits *ULK1* and ULK2 with IC₅₀s of 45 and 38 nM, respectively. MRT67307 hydrochloride also blocks autophagy in cells .

HY-13018B

MRT67307 dihydrochloride	IKK ULK Autophagy	Inflammation/Immunology Cancer
MRT67307 dihydrochloride is a dual inhibitor of the IKKε and *TBK-1* with IC₅₀s of 160 and 19 nM, respectively ^[1]. MRT67307 dihydrochloride also inhibits *ULK1* and ULK2 with IC₅₀s of 45 and 38 nM, respectively. MRT67307 dihydrochloride also blocks autophagy in cells .

HY-110341

MRT 68601 hydrochloride	IKK	Cancer
MRT 68601 hydrochloride is a *TBK1* inhibitor with an IC₅₀ value of 6 nM. MRT 68601 hydrochloride inhibits autophagosome formation in lung cancer cells ^[1] .

HY-133117A

(Rac)-BAY-985

IKK Cancer

(Rac)-BAY-985 (Compound Example 100.01) is a potent, ATP-competitive and selective TBK1 inhibitor with an IC₅₀ of 1.5 nM. Antitumor efficacy ^[1].

(Rac)-BAY-985	IKK	Cancer
(Rac)-BAY-985 (Compound Example 100.01) is a potent, ATP-competitive and selective *TBK1* inhibitor with an IC₅₀ of 1.5 nM. Antitumor efficacy ^[1].

HY-14682

GSK319347A 1 Publications Verification	IKK	Inflammation/Immunology
GSK319347A is a dual inhibitor of *TBK1* and IKKε with IC₅₀s of 93 nM and 469 nM, respectively. GSK319347A also inhibits IKK2 with an IC₅₀ of 790 nM.

HY-160477

DC-SX029	PIKfyve NF-κB IKK	Inflammation/Immunology
DC-SX029 is a potent SNX10 protein-protein interaction (PPI) inhibitor with an estimated K_D constant of ~0.935 μM by surface plasmon resonance (SPR). DC-SX029 blocks the SNX10-PIKfyve interaction, thereby decreased the TBK1/c-Rel signaling activation. DC-SX029 does not affect the protein level of SNX10. DC-SX029 has the potential for inflammatory bowel disease (IBD) research ^[1].

HY-12326A

c-di-AMP disodium 2 Publications Verification Cyclic diadenylate disodium; Cyclic-di-AMP disodium	STING Bacterial Endogenous Metabolite	Inflammation/Immunology
c-di-AMP (Cyclic diadenylate) sodium is a STING agonist, which binds to the transmembrane protein STING thereby activating the TBK3-IRF3 signaling pathway, subsequently triggering the production of type I IFN and TNF. c-di-AMP sodium is also a bacterial second messenger, which regulates cell growth, survival, and virulence, primarily within Gram-positive bacteria, and also regulates host immune response. c-di-AMP sodium acts as a potent mucosal adjuvant stimulating both humoral and cellular responses ^[1] .

HY-12326B

c-di-AMP diammonium 2 Publications Verification Cyclic diadenylate diammonium; Cyclic-di-AMP diammonium	STING Bacterial Endogenous Metabolite	Inflammation/Immunology
c-di-AMP diammonium is a STING agonist, which binds to the transmembrane protein STING thereby activating the TBK3-IRF3 signaling pathway, subsequently triggering the production of type I IFN and TNF. c-di-AMP diammonium is also a bacterial second messenger, which regulates cell growth, survival, and virulence, primarily within Gram-positive bacteria, and also regulates host immune response. c-di-AMP diammonium acts as a potent mucosal adjuvant stimulating both humoral and cellular responses ^[1] .

HY-12326

c-di-AMP Cyclic diadenylate; Cyclic-di-AMP	STING Bacterial Endogenous Metabolite	Inflammation/Immunology
c-di-AMP (Cyclic diadenylate) is a STING agonist, which binds to the transmembrane protein STING thereby activating the TBK3-IRF3 signaling pathway, subsequently triggering the production of type I IFN and TNF. c-di-AMP (Cyclic diadenylate) is also a bacterial second messenger, which regulates cell growth, survival, and virulence, primarily within Gram-positive bacteria, and also regulates host immune response. c-di-AMP (Cyclic diadenylate) acts as a potent mucosal adjuvant stimulating both humoral and cellular responses ^[1] .

HY-160225

ISD sodium	STING	Inflammation/Immunology
non-CpG oligomer from the Listeria monocytogenes genome. When transfected into cells, ISD sodium strongly enhances the expression of IFN-β. This ISD-induced response is mediated by the STING-TBK1-IRF3 signaling axis ^[1].

HY-112693

H-151 Maximum Cited Publications 38 Publications Verification	STING	Inflammation/Immunology
H-151 is a potent, selective and covalent antagonist of STING that has noteworthy inhibitory activity both in cells and in vivo. H-151 reduces TBK1 phosphorylation and suppresses STING palmitoylation. H-151 can be used for the research of autoinflammatory disease ^[1].

HY-12326R

c-di-AMP (Standard) Cyclic diadenylate (Standard); Cyclic-di-AMP (Standard)	STING Bacterial Endogenous Metabolite	Inflammation/Immunology
c-di-AMP (Standard) is the analytical standard of c-di-AMP. This product is intended for research and analytical applications. c-di-AMP (Cyclic diadenylate) is a STING agonist, which binds to the transmembrane protein STING thereby activating the TBK3-IRF3 signaling pathway, subsequently triggering the production of type I IFN and TNF. c-di-AMP (Cyclic diadenylate) is also a bacterial second messenger, which regulates cell growth, survival, and virulence, primarily within Gram-positive bacteria, and also regulates host immune response. c-di-AMP (Cyclic diadenylate) acts as a potent mucosal adjuvant stimulating both humoral and cellular responses ^[1] .

HY-10514

BX795 20+ Cited Publications	PDK-1 IKK Autophagy	Cancer
BX795 is a potent and selective inhibitor of *PDK1, with an IC₅₀* of 6 nM. BX795 is also a potent and relatively specific inhibitor of *TBK1* and IKKε, with an IC₅₀ of 6 and 41 nM, respectively. BX795 blocks phosphorylation of S6K1, Akt, PKCδ, and GSK3β, and has lower selectivity over PKA, PKC, c-Kit, GSK3β etc. BX795 modulates autophagy ^[1] .

HY-152956

STING agonist-23	STING	Infection
STING agonist-23 (CF502) is a non-nucleotide small-molecule STING agonist. STING agonist-23 activates STING, increases phosphorylation of STING, *TBK1* and IRF3. STING agonist-23 promotes the levels of IFN-β, IL-6, CXCL-10, TNF-α, ISG-15, and CCL-5 in tumor cells. STING agonist-23 exhibits activity against SARS-CoV series strains ^[1].

HY-152957

STING agonist-24	STING	Infection
STING agonist-24 (CF504) is a non-nucleotide small-molecule STING agonist. STING agonist-23 activates STING, increases phosphorylation of STING, *TBK1* and IRF3. STING agonist-23 promotes the levels of IFN-β, IL-6, CXCL-10, TNF-α, ISG-15, and CCL-5 in tumor cells. STING agonist-23 exhibits activity against SARS-CoV series strains ^[1].

HY-152958

STING agonist-25	STING	Infection
STING agonist-25 (CF505) is a non-nucleotide small-molecule STING agonist. STING agonist-23 activates STING, increases phosphorylation of STING, *TBK1* and IRF3. STING agonist-23 promotes the levels of IFN-β, IL-6, CXCL-10, TNF-α, ISG-15, and CCL-5 in tumor cells. STING agonist-23 exhibits activity against SARS-CoV series strains ^[1].

HY-152959

STING agonist-26	STING	Infection
STING agonist-26 (CF508) is a non-nucleotide small-molecule STING agonist. STING agonist-23 activates STING, increases phosphorylation of STING, *TBK1* and IRF3. STING agonist-23 promotes the levels of IFN-β, IL-6, CXCL-10, TNF-α, ISG-15, and CCL-5 in tumor cells. STING agonist-23 exhibits activity against SARS-CoV series strains ^[1].

HY-152961

STING agonist-28	STING	Infection
STING agonist-28 (CF510) is a non-nucleotide small-molecule STING agonist. STING agonist-23 activates STING, increases phosphorylation of STING, *TBK1* and IRF3. STING agonist-23 promotes the levels of IFN-β, IL-6, CXCL-10, TNF-α, ISG-15, and CCL-5 in tumor cells. STING agonist-23 exhibits activity against SARS-CoV series strains ^[1].

HY-160222

HSV-60mer sodium	HSV STING	Infection Inflammation/Immunology
HSV-60mer sodium is a 60 bp double-stranded oligonucleotide containing viral DNA motifs that derive from the herpes simplex virus 1 (HSV-1) genome ^[1]. Transfected HSV-60 has been shown to potently induce IFN-β in a Toll-like receptor (TLR)-, DNA-dependent activator of IRFs (DAI)-, and RNA polymerase III (Pol III)-independent, but STING-, TBK1- and IFN regulatory factor 3 (IRF3)-dependent manner.

Cat. No.	Product Name	Category	Target	Chemical Structure